PHARMACY

FDA approves Endo generic Plendil

BY Alaric DeArment

CHADDS FORD, Pa. — The Food and Drug Administration has approved a drug made by Endo Pharmaceuticals for high blood pressure.

Endo announced Wednesday the approval of felodipine extended-release tablets in the 2.5-mg, 5-mg and 10-mg strengths. Endo’s generic drugs division, Qualitest Pharmaceuticals, will manufacture and distribute the product.

The drug is a generic version of AstraZeneca’s Plendil extended-release tablets. Felodipine had sales of about $84 million during the 12-month period ended in June, according to IMS Health.


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Perrigo seeks approval for generic version of Abbott’s Androgel

BY Alaric DeArment

ALLEGAN, Mich. — Drug maker Perrigo has filed for regulatory approval of a generic topical drug for treating testosterone deficiency, prompting a patent infringement suit from the branded version’s manufacturer.

Perrigo announced Wednesday that it had applied for Food and Drug Administration approval of testosterone gel in the 1% strength, a generic version of Abbott’s Androgel, used to treat men with low or no testosterone. In response, Abbott filed suit against Perrigo in the U.S. District Court for the District of New Jersey on Monday, alleging that Perrigo’s filing infringes Abbot’s patent on the drug.

Androgel has annual sales of about $900 million, according to Wolters Kluwer Health.


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Polyglot Systems enters partnership with Family Health Network

BY Allison Cerra

RESEARCH TRIANGLE PARK, N.C. — A provider of software-based communication solutions for the healthcare realm will integrate one of its technologies into an online program that allows healthcare providers and caregivers to remotely monitor, record and track patients’ health status and medication use on a daily basis.

Polyglot Systems said its Meducation technology will be implemented into the Connected for Life platform, which is operated by the Family Health Network.

“We are thrilled to be partnering with Family Health Network,” Polyglot Systems CEO Sims Preston said. By integrating with their Connected for Life technology, we will have new resources to deliver Meducation content to patients. The opportunities for improving patient health and reducing healthcare costs are tremendous.”

Family Health Network CEO Harry Bailes said, “Increasing patient understanding improves health and drives down costs. It’s critical that health information be delivered in ways that are easy to understand,” he said. “Our Connected for Life platform has been acclaimed for its ability to enhance patient-provider communication with its user-friendly, patient-centered design. Polyglot’s Meducation technology is a natural fit and complements our focus on effective communication.”


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?